Dr. Hamid on TMB as a Biomarker for Immunotherapy Response in Melanoma

Source: OncLive, August 2020

Omid Hamid, MD, director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute, discusses the utility of tumor mutational burden (TMB) as a biomarker for response to immunotherapy in patients with melanoma.

TMB is not just for melanoma, says Hamid. By examining TMB, investigators have done a significant job in helping to understand which patients will respond best to immunotherapy across a multitude of tumor types.

Investigators have looked at high TMBs to determine response to immunotherapy within the context of CTLA-4 and PD-1 inhibitors; several papers have analyzed this.

READ THE ORIGINAL FULL ARTICLE